LT3880654T - 2-formil-3-hidroksifeniloksimetilo junginiai, galintys moduliuoti hemoglobiną - Google Patents
2-formil-3-hidroksifeniloksimetilo junginiai, galintys moduliuoti hemoglobinąInfo
- Publication number
- LT3880654T LT3880654T LTEPPCT/US2019/062054T LTUS2019062054T LT3880654T LT 3880654 T LT3880654 T LT 3880654T LT US2019062054 T LTUS2019062054 T LT US2019062054T LT 3880654 T LT3880654 T LT 3880654T
- Authority
- LT
- Lithuania
- Prior art keywords
- hydroxyphenyloxymethyl
- formyl
- compounds capable
- hemoglobin
- modulating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862769196P | 2018-11-19 | 2018-11-19 | |
US201962821314P | 2019-03-20 | 2019-03-20 | |
US201962848773P | 2019-05-16 | 2019-05-16 | |
US201962883313P | 2019-08-06 | 2019-08-06 | |
PCT/US2019/062054 WO2020106642A1 (en) | 2018-11-19 | 2019-11-18 | 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin |
Publications (1)
Publication Number | Publication Date |
---|---|
LT3880654T true LT3880654T (lt) | 2022-02-25 |
Family
ID=68848454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEPPCT/US2019/062054T LT3880654T (lt) | 2018-11-19 | 2019-11-18 | 2-formil-3-hidroksifeniloksimetilo junginiai, galintys moduliuoti hemoglobiną |
Country Status (27)
Country | Link |
---|---|
US (3) | US10683285B2 (lt) |
EP (2) | EP3880654B1 (lt) |
JP (1) | JP7509772B2 (lt) |
KR (1) | KR20210093990A (lt) |
CN (1) | CN113316568A (lt) |
AU (1) | AU2019383960A1 (lt) |
BR (1) | BR112021007044B1 (lt) |
CA (1) | CA3120380A1 (lt) |
CO (1) | CO2021007993A2 (lt) |
CR (1) | CR20210335A (lt) |
CY (1) | CY1125025T1 (lt) |
DK (1) | DK3880654T3 (lt) |
ES (1) | ES2908325T3 (lt) |
HR (1) | HRP20220295T1 (lt) |
HU (1) | HUE057323T2 (lt) |
IL (1) | IL283128A (lt) |
LT (1) | LT3880654T (lt) |
MA (1) | MA54231B1 (lt) |
MD (1) | MD3880654T2 (lt) |
MX (1) | MX2021005887A (lt) |
PL (1) | PL3880654T3 (lt) |
PT (1) | PT3880654T (lt) |
RS (1) | RS62970B1 (lt) |
SA (1) | SA521422031B1 (lt) |
SG (1) | SG11202104705RA (lt) |
SI (1) | SI3880654T1 (lt) |
WO (1) | WO2020106642A1 (lt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2015011448A (es) | 2013-03-15 | 2016-06-06 | Global Blood Therapeutics Inc | Compuestos y sus usos para modular la hemoglobina. |
SG11201507453VA (en) | 2013-03-15 | 2015-10-29 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
ES2852054T3 (es) | 2013-03-15 | 2021-09-10 | Global Blood Therapeutics Inc | Compuestos y usos de los mismos para la modulación de hemoglobina |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
EP3868745A1 (en) | 2014-02-07 | 2021-08-25 | Global Blood Therapeutics, Inc. | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
WO2017096230A1 (en) | 2015-12-04 | 2017-06-08 | Global Blood Therapeutics, Inc. | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
AU2018240172C1 (en) | 2017-03-20 | 2019-10-24 | Novo Nordisk Health Care Ag | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators |
CN113226356A (zh) | 2018-09-19 | 2021-08-06 | 福马治疗股份有限公司 | 活化丙酮酸激酶r |
US10675274B2 (en) | 2018-09-19 | 2020-06-09 | Forma Therapeutics, Inc. | Activating pyruvate kinase R |
EP3860975B1 (en) | 2018-10-01 | 2023-10-18 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin for the treatment of sickle cell disease |
RS62970B1 (sr) * | 2018-11-19 | 2022-03-31 | Global Blood Therapeutics Inc | 2-formil-3-hidroksifeniloksimetil jedinjenja sposobna da moduliraju hemoglobin |
AR126648A1 (es) * | 2021-05-14 | 2023-11-01 | Global Blood Therapeutics Inc | Métodos para hacer un modulador de hemoglobina |
EP4337659A1 (en) | 2021-05-14 | 2024-03-20 | Global Blood Therapeutics, Inc. | Solid forms of a modulator of hemoglobin |
WO2023003332A1 (ko) | 2021-07-19 | 2023-01-26 | 주식회사 바이오앱 | 식물 기반 covid-19 변이 재조합 스파이크 단백질 발현 벡터 및 상기 발현 벡터를 이용한 재조합 단백질 |
TW202339732A (zh) * | 2021-12-10 | 2023-10-16 | 美商全球血液治療公司 | 投予血紅素調節劑的方法 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
AU545274B2 (en) | 1979-06-29 | 1985-07-11 | Wellcome Foundation Limited, The | 5-(2-formyl-3-hydroxyphenoxy) - pentanoic acid derivatives |
US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
DK160866C (da) | 1980-12-18 | 1991-10-14 | Wellcome Found | Analogifremgangsmaade til fremstilling af phenoletherforbindelser |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
JPS63258463A (ja) | 1987-04-14 | 1988-10-25 | Kumiai Chem Ind Co Ltd | 2−フエノキシピリミジン誘導体及び除草剤 |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
EP0658559A1 (de) | 1993-12-14 | 1995-06-21 | Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. | Thienothiazinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als 5-dipoxygenase und Cyclooxygenaseinhibitoren |
TR200101744T2 (tr) | 1998-12-14 | 2001-12-21 | F. Hoffmann-La Roche Ag | Fenilglisin türevleri. |
ES2203443T3 (es) | 1999-03-31 | 2004-04-16 | Basf Aktiengesellschaft | Compuestos de anilina substituidos. |
BR0313160A (pt) | 2002-08-08 | 2005-07-12 | Smithkline Beecham Corp | Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto |
ATE527238T1 (de) | 2002-12-04 | 2011-10-15 | Univ Virginia Commonwealth | Mittel mit wirkung gegen sichelzellenanämie |
JP2006527210A (ja) | 2003-06-12 | 2006-11-30 | ノボ ノルディスク アクティーゼルスカブ | ホルモン感受性リパーゼ阻害剤としてのピリジニルカルバメート |
EP1745012A4 (en) | 2004-04-22 | 2010-11-03 | Univ Virginia Commonwealth | COMPOSITIONS OF ALLOSTERIC HEMOGLOBIN MODIFYING SUBSTANCES AND METHOD FOR THE PRODUCTION THEREOF |
NZ564759A (en) | 2005-06-30 | 2011-08-26 | Prosidion Ltd | GPCR agonists |
CN100562514C (zh) | 2005-07-22 | 2009-11-25 | 中国科学院上海药物研究所 | 一类取代丙酰胺衍生物、其制备方法和用途 |
TW200835687A (en) | 2006-11-30 | 2008-09-01 | R Tech Ueno Ltd | Thiazole derivatives and their use as VAP-1 inhibitor |
WO2009011850A2 (en) | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
KR101538822B1 (ko) | 2008-05-08 | 2015-07-22 | 노바 사우쓰이스턴 유니버시티 | 혈관 내피 성장 인자 수용체에 대한 특이적 억제제 |
GB0811451D0 (en) | 2008-06-20 | 2008-07-30 | Syngenta Participations Ag | Novel microbiocides |
TW201033201A (en) | 2009-02-19 | 2010-09-16 | Hoffmann La Roche | Isoxazole-isoxazole and isoxazole-isothiazole derivatives |
ES2790358T3 (es) | 2011-12-28 | 2020-10-27 | Global Blood Therapeutics Inc | Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular |
EP3141542B1 (en) | 2011-12-28 | 2020-05-27 | Global Blood Therapeutics, Inc. | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
AU2014237361A1 (en) * | 2013-03-15 | 2015-09-17 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
US20150057251A1 (en) | 2013-08-26 | 2015-02-26 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
MX2015011448A (es) | 2013-03-15 | 2016-06-06 | Global Blood Therapeutics Inc | Compuestos y sus usos para modular la hemoglobina. |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US20140271591A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compositions and methods for the modulation of hemoglobin (s) |
US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
ES2852054T3 (es) | 2013-03-15 | 2021-09-10 | Global Blood Therapeutics Inc | Compuestos y usos de los mismos para la modulación de hemoglobina |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US20160206604A1 (en) | 2013-08-26 | 2016-07-21 | Global Blood Therapeutics, Inc. | Formulations comprising wetting agents and compounds for the modulation of hemoglobin (s) |
US20160207904A1 (en) | 2013-08-27 | 2016-07-21 | Global Blood Therapeutics, Inc. | Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts |
US20150141465A1 (en) | 2013-11-18 | 2015-05-21 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
EA202092627A1 (ru) | 2013-11-18 | 2021-09-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
US9248199B2 (en) | 2014-01-29 | 2016-02-02 | Global Blood Therapeutics, Inc. | 1:1 adducts of sickle hemoglobin |
EP3868745A1 (en) | 2014-02-07 | 2021-08-25 | Global Blood Therapeutics, Inc. | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
WO2017096230A1 (en) | 2015-12-04 | 2017-06-08 | Global Blood Therapeutics, Inc. | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
TWI663160B (zh) | 2016-05-12 | 2019-06-21 | 全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
RS62970B1 (sr) * | 2018-11-19 | 2022-03-31 | Global Blood Therapeutics Inc | 2-formil-3-hidroksifeniloksimetil jedinjenja sposobna da moduliraju hemoglobin |
-
2019
- 2019-11-18 RS RS20220126A patent/RS62970B1/sr unknown
- 2019-11-18 SI SI201930191T patent/SI3880654T1/sl unknown
- 2019-11-18 CR CR20210335A patent/CR20210335A/es unknown
- 2019-11-18 SG SG11202104705RA patent/SG11202104705RA/en unknown
- 2019-11-18 KR KR1020217018851A patent/KR20210093990A/ko unknown
- 2019-11-18 HU HUE19818401A patent/HUE057323T2/hu unknown
- 2019-11-18 PL PL19818401T patent/PL3880654T3/pl unknown
- 2019-11-18 JP JP2021527206A patent/JP7509772B2/ja active Active
- 2019-11-18 HR HRP20220295TT patent/HRP20220295T1/hr unknown
- 2019-11-18 LT LTEPPCT/US2019/062054T patent/LT3880654T/lt unknown
- 2019-11-18 DK DK19818401.2T patent/DK3880654T3/da active
- 2019-11-18 AU AU2019383960A patent/AU2019383960A1/en active Pending
- 2019-11-18 MA MA54231A patent/MA54231B1/fr unknown
- 2019-11-18 MD MDE20210907T patent/MD3880654T2/ro unknown
- 2019-11-18 MX MX2021005887A patent/MX2021005887A/es unknown
- 2019-11-18 CN CN201980088809.5A patent/CN113316568A/zh active Pending
- 2019-11-18 WO PCT/US2019/062054 patent/WO2020106642A1/en active Application Filing
- 2019-11-18 US US16/687,474 patent/US10683285B2/en active Active
- 2019-11-18 CA CA3120380A patent/CA3120380A1/en active Pending
- 2019-11-18 EP EP19818401.2A patent/EP3880654B1/en active Active
- 2019-11-18 PT PT198184012T patent/PT3880654T/pt unknown
- 2019-11-18 ES ES19818401T patent/ES2908325T3/es active Active
- 2019-11-18 BR BR112021007044-3A patent/BR112021007044B1/pt active IP Right Grant
- 2019-11-18 EP EP21217304.1A patent/EP4046988A1/en active Pending
-
2020
- 2020-05-04 US US16/865,625 patent/US11548880B2/en active Active
-
2021
- 2021-05-12 IL IL283128A patent/IL283128A/en unknown
- 2021-05-17 SA SA521422031A patent/SA521422031B1/ar unknown
- 2021-06-18 CO CONC2021/0007993A patent/CO2021007993A2/es unknown
-
2022
- 2022-02-28 CY CY20221100163T patent/CY1125025T1/el unknown
- 2022-11-21 US US17/991,448 patent/US20230159507A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL283128A (en) | 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin | |
IL271149A (en) | Compounds for modulating s1p1 activity and methods of using them | |
EP3768854A4 (en) | HSD17B13 EXPRESSION MODULATORS | |
GB201804514D0 (en) | Treatment of pyroptosis | |
IL281492A (en) | Modulators of PNPLA3 expression | |
IL283672A (en) | trex1 modulators | |
IL283967A (en) | Modulators of hsd17b13 expression | |
IL283408A (en) | Pyrazoles as modulators of hemoglobin | |
IL262623A (en) | tourniquet | |
GB201804515D0 (en) | Treatment of necroptosis | |
IL256055B (en) | Using h3k9me3 modulation to enhance cognitive function | |
EP3259256A4 (en) | COMPOUNDS AND METHODS FOR INDUCING BROWNING OF WHITE ADIPOSE TISSUE | |
EP3302696A4 (en) | Patient specific frequency modulation adaption | |
IL282731A (en) | Organogulfonic compounds | |
ZA201907406B (en) | Trpv1 modulator compounds | |
SG11202105136WA (en) | Application of chidamide | |
EP3548620A4 (en) | MODULATION OF THE EXPRESSION OF LNC05 | |
GB201918992D0 (en) | GPR52 modulator compounds | |
GB201918974D0 (en) | Gpr52 modulator compounds | |
GB201916298D0 (en) | GPR52 modulator compounds | |
GB201821093D0 (en) | Treatment of hydrocarbons | |
GB201710054D0 (en) | PBC compounds | |
EP3446689A4 (en) | USE OF ISOTHIOCYANATE COMPOUNDS | |
PT3377106T (pt) | Modulação da ciliogénese | |
GB201701928D0 (en) | Compounds for the treatment of hyperglycaemia |